Spyre Therapeutics (SYRE) EPS (Basic) (2015 - 2026)
Spyre Therapeutics (SYRE) reported EPS (Basic) of -$0.74 for Q1 2026, up 96.91% on a YoY basis from -$0.38 in Q1 2025, and up 99.05% quarter-over-quarter from -$77.78 in Q4 2025.
Spyre Therapeutics (SYRE) EPS (Basic) (2015 - 2026) Analysis & Trends
Spyre Therapeutics has reported EPS (Basic) for 12 years, with the latest figure at -$0.74 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Basic) rose 96.91% year-over-year to -$0.74; the trailing twelve-month figure through Mar 2026 stood at -$104.11 (down 14.92% YoY), and the FY2025 full-year result was -$79.02, down 2384.91% from the prior year.
- EPS (Basic) for Q1 2026 stood at -$0.74, up from -$77.78 in the prior quarter.
- The five-year high for EPS (Basic) was $40.14 in Q2 2023, with the low at -$77.78 in Q4 2025.
- Historically, EPS (Basic) has averaged -$13.3 across 5 years, with a median of -$4.89 in 2023.
- Annual changes were most pronounced in 2023 — EPS (Basic) soared 14966.67% — and 2025, when it plunged 9745.57%.
- Spyre Therapeutics' EPS (Basic) stood at -$4.69 in 2022, then tumbled by 505.76% to -$28.41 in 2023, then soared by 97.22% to -$0.79 in 2024, then sank by 9745.57% to -$77.78 in 2025, then jumped by 99.05% to -$0.74 in 2026.
- The last three EPS (Basic) figures came in at -$0.74 (Q1 2026), -$77.78 (Q4 2025), and -$5.97 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 0.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.06 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.06 |
| 10 | Spyre Therapeutics | 6.95 Bn | 6.95 Bn | - | -0.74 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.74 |
| Dec 31, 2025 | -77.78 |
| Sep 30, 2025 | -5.97 |
| Jun 30, 2025 | -19.62 |
| Mar 31, 2025 | -23.95 |
| Dec 31, 2024 | -0.79 |
| Sep 30, 2024 | -42.24 |
| Jun 30, 2024 | -23.61 |
| Mar 31, 2024 | -28.93 |
| Dec 31, 2023 | -28.41 |
| Sep 30, 2023 | 0.86 |
| Jun 30, 2023 | 40.14 |
| Mar 31, 2023 | -4.89 |
| Dec 31, 2022 | -4.69 |
| Sep 30, 2022 | -4.84 |
| Jun 30, 2022 | -0.27 |
| Mar 31, 2022 | -0.37 |
| Dec 31, 2021 | 0.69 |
| Sep 30, 2021 | -0.31 |
| Jun 30, 2021 | -0.10 |